Mora Barthelmess Romina, Stijlemans Benoit, Van Ginderachter Jo A
Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, 1050 Brussels, Belgium.
Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, 1050 Brussels, Belgium.
Cancers (Basel). 2023 Jan 6;15(2):395. doi: 10.3390/cancers15020395.
New diagnostic methods and treatments have significantly decreased the mortality rates of cancer patients, but further improvements are warranted based on the identification of novel tumor-promoting molecules that can serve as therapeutic targets. The macrophage migration inhibitory factor (MIF) family of cytokines, comprising MIF and DDT (also known as MIF2), are overexpressed in almost all cancer types, and their high expressions are related to a worse prognosis for the patients. MIF is involved in 9 of the 10 hallmarks of cancer, and its inhibition by antibodies, nanobodies, or small synthetic molecules has shown promising results. Even though DDT is also proposed to be involved in several of the hallmarks of cancer, the available information about its pro-tumoral role and mechanism of action is more limited. Here, we provide an overview of the involvement of both MIF and DDT in cancer, and we propose that blocking both cytokines is needed to obtain the maximum anti-tumor response.
新的诊断方法和治疗手段显著降低了癌症患者的死亡率,但基于对可作为治疗靶点的新型促肿瘤分子的识别,仍有必要进一步改进。细胞因子巨噬细胞迁移抑制因子(MIF)家族,包括MIF和DDT(也称为MIF2),在几乎所有癌症类型中均过度表达,其高表达与患者较差的预后相关。MIF参与了癌症的10个特征中的9个,通过抗体、纳米抗体或小分子合成物对其进行抑制已显示出有前景的结果。尽管DDT也被认为参与了癌症的几个特征,但其促肿瘤作用及其作用机制的现有信息更为有限。在此,我们概述了MIF和DDT在癌症中的参与情况,并提出需要同时阻断这两种细胞因子才能获得最大的抗肿瘤反应。